224 related articles for article (PubMed ID: 12966450)
21. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty.
Spruill WJ; Wade WE; Leslie RB
Am J Ther; 2004; 11(1):3-8. PubMed ID: 14704589
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
de Lissovoy G; Subedi P
Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
[TBL] [Abstract][Full Text] [Related]
24. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
25. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
Tran AH; Lee G
Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
[TBL] [Abstract][Full Text] [Related]
26. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.
Bjorvatn A; Kristiansen F
Am J Cardiovasc Drugs; 2005; 5(2):121-30. PubMed ID: 15725043
[TBL] [Abstract][Full Text] [Related]
27. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma.
Devlin JW; Petitta A; Shepard AD; Obeid FN
Pharmacotherapy; 1998; 18(6):1335-42. PubMed ID: 9855335
[TBL] [Abstract][Full Text] [Related]
29. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Schiff RL; Kahn SR; Shrier I; Strulovitch C; Hammouda W; Cohen E; Zukor D
Chest; 2005 Nov; 128(5):3364-71. PubMed ID: 16304285
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
Sullivan SD; Kwong L; Nutescu E
Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
[TBL] [Abstract][Full Text] [Related]
31. A retrospective study on the use of a low-molecular-weight heparin for thromboembolism prophylaxis in large-volume liposuction and body contouring procedures.
Newall G; Ruiz-Razura A; Mentz HA; Patronella CK; Ibarra FR; Zarak A
Aesthetic Plast Surg; 2006; 30(1):86-95; discussion 96-7. PubMed ID: 16404651
[TBL] [Abstract][Full Text] [Related]
32. An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.
Reeves P; Cooke J; Lloyd A; Hutchings A
Pharm World Sci; 2004 Jun; 26(3):160-8. PubMed ID: 15230364
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
[TBL] [Abstract][Full Text] [Related]
34. Economic considerations in the prevention and treatment of venous thromboembolism.
Hawkins D
Am J Health Syst Pharm; 2004 Dec; 61(23 Suppl 7):S18-21. PubMed ID: 15597575
[TBL] [Abstract][Full Text] [Related]
35. [Prevention of venous thromboembolism in internal medicine and neurology].
Malý J; Dulícek P; Penka M; Malý R; Gumulec J
Vnitr Lek; 2006 Mar; 52 Suppl 1():63-7. PubMed ID: 16637452
[TBL] [Abstract][Full Text] [Related]
36. Clinical application of enoxaparin.
Hofmann T
Expert Rev Cardiovasc Ther; 2004 May; 2(3):321-37. PubMed ID: 15151480
[TBL] [Abstract][Full Text] [Related]
37. Venous thromboembolism prophylaxis conversion in nonsurgical inpatients.
Carroll DN; Hudson EB
Ann Pharmacother; 2003 Sep; 37(9):1194-6. PubMed ID: 12921498
[TBL] [Abstract][Full Text] [Related]
38. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
[TBL] [Abstract][Full Text] [Related]
39. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice.
Menown I; Montalescot G; Pal N; Fidler C; Orme M; Gillard S
Adv Ther; 2010 Mar; 27(3):181-91. PubMed ID: 20422473
[TBL] [Abstract][Full Text] [Related]
40. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
Kleber FX; Witt C; Vogel G; Koppenhagen K; Schomaker U; Flosbach CW;
Am Heart J; 2003 Apr; 145(4):614-21. PubMed ID: 12679756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
